Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Human vaccines & immunotherapeutics
- Publicado em
- 14 dez 2021
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial
Xiaoyu Liu, Wanqi Yang, Chao Zhang, Heng Wu, Ruize Wang, Qiang Ding, Yan Hu, Yongli Xiong, Shaobai Zhang, Lin Wang
Descritores MeSH
- Rubella
- Encephalitis Virus, Japanese
- Enterovirus
- Japanese Encephalitis Vaccines
- Measles
- Enterovirus A, Human
- Mumps
- Antibodies, Neutralizing
- Humans
- Infant
Veja também
Estudos relacionados
- Immunogenicity and safety of the inactivated enterovirus 71 vaccine administered concomitantly with the measles-rubella vaccine in infants aged 8 months in China: A noninferiority randomized controlled trial
- Evaluation of the Safety and Immunogenicity of M-M-RII (Combination Measles-mumps-rubella Vaccine): Clinical Trials of Healthy Children and Adults Published Between 2010 and 2019
- Use of M-M-R II outside of the routinely recommended age range - a systematic literature review
- Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial